The latest edition of the publication "Mindfield - The Bulletin of the Parapsychological Association" devotes some of its pages to the BIAL Foundation, highlighting it contribution to the study and research in parapsychology.
The BIAL Foundation has received 62 applications to the 15th edition of the BIAL Award, considered one of the most prestigious prizes of scientific research in healthcare throughout Europe
BIAL Group is one of the three Portuguese companies that most invest in R&D, according to the study "The 2012 EU Industrial R&D Investment Scoreboard".
The BIAL Group officially inaugurated its new Integrated Unit of Production and Research, located in the Science and Technology Park of Biscay,
In Bilbao, Spain. The official opening ceremony was chaired by His Royal Highness the Prince of Asturias, counting also with the presence of personalities of the Portuguese and Spanish Government-and other institutional representatives of the Basque Country.
The BIAL Foundation fellow Magne Flaten published the full paper “Variability in placebo analgesia and the role of fear of pain—an ERP study” in the prestigious journal "PAIN".
BIAL invested 12 million Euros in a new plant in the Science and Technology Park of Biscay, in Bilbao, Spain, for the production and research of immunotherapy.
BIAL Foundation has just opened applications to the 15th edition of BIAL Award, one of the most prestigious awards of scientific research in the area of health in Europe.
BIAL reached 17th place in RepTrak™ Pulse 2011 Portugal - "Portugal’s most reputable companies". The result (80.01) indicates an Excellent reputation of BIAL by the general public.
The new antiepileptic drug from the BIAL Group has just been launched in Greece and in the Republic of Ireland after reaching reimbursement agreements. The launch in these markets comes under the license agreement and co-promotion signed between BIAL and the multinational Eisai, in February 2009, for marketing the drug in several European countries.
Zebinix® (eslicarbazepine acetate), an add-on (adjunctive) therapy for adults with partial-onset seizures, with or without secondary generalisation (where the seizure spreads to both sides of the brain), has been launched today in Spain by Eisai and BIAL in a co-promotion.
BIAL Group ranks fourth, and first in the area of health, in the ranking of the 100 companies with more investment in research and development (R&D) in 2008 in Portugal.
BIAL was voted the best Portuguese company operating in Spain by the Câmara Hispano Portuguesa, which aims to spotlight the growth and consolidation of firms in the Iberian market.
The BIAL Award, one of the most prestigious awards of scientific research in the area of health in Europe, is accepting applications until the end of October.